N-((N-甲基-N-((2-异丙基-4-噻唑基)甲基)氨基)甲酰)-L-缬氨酸甲酯 | 154248-99-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 缬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-((N-甲基-N-((2-异丙基-4-噻唑基)甲基)氨基)甲酰)-L-缬氨酸甲酯
• 英文名称: N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine methyl ester
• 英文别名: N-<amino>carbonyl>-L-valine methyl ester；methyl (2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoate
• CAS: 154248-99-4
• 化学式: C₁₅H₂₅N₃O₃S
• 分子量: 327.448
• InChiKey: WMOQPDKCUZISQT-LBPRGKRZSA-N

物化性质

• 熔点：
  73-74°C
• 沸点：
  490.9±35.0 °C(Predicted)
• 密度：
  1.136
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  99.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-((N-甲基-N-((2-异丙基-4-噻唑基)甲基)氨基)甲酰)-L-缬氨酸甲酯 在 lithium hydroxide 、 N-ethyl-N’-(diethylaminopropyl)-carbodiimide 、 1-羟基苯并三唑一水物 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 16.5h， 生成 利托那韦
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+
• 作为产物：
  描述：

  4-(Chloromethyl)-2-isopropylthiazole Hydrochloride 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 N-((N-甲基-N-((2-异丙基-4-噻唑基)甲基)氨基)甲酰)-L-缬氨酸甲酯
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+

文献信息

• Pharmaceutical composition
  申请人：Abbott Laboratories

  公开号：US05559158A1

  公开（公告）日：1996-09-24

  A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

  揭示了一种固体药物组合物，包括一种药学上可接受的吸附剂或一种药学上可接受的吸附剂混合物，该吸附剂或吸附剂混合物吸附了（1）一种药学上可接受的有机溶剂或一种药学上可接受的有机溶剂混合物，（2）一种HIV蛋白酶抑制化合物和（3）一种或多种药学上可接受的酸。该固体组合物可以选择性地封装在硬明胶胶囊中。
• Pharmaceutical composition for inhibiting HIV protease
  申请人：Abbott Laboratories

  公开号：US05484801A1

  公开（公告）日：1996-01-16

  A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.

  一种药物组合物被披露，其包括一种HIV蛋白酶抑制化合物的溶液，所述溶液在一种药用可接受的有机溶剂中，所述有机溶剂包括以下混合物：(1) (a) 从丙二醇和聚乙二醇中选择的溶剂，或者 (b) 从聚氧乙烯甘油三蓖麻油酸酯、聚乙二醇40氢化蓖麻油、分馏椰子油、聚氧乙烯(20)山梨醇单油酸酯和2-(2-乙氧基乙氧基)乙醇中选择的溶剂，或者 (c) 其混合物，以及 (2) 乙醇或丙二醇。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05461067A1

  公开（公告）日：1995-10-24

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed wherein R.sub.1, R.sub.2, R.sub.5, R.sub.6, Y.sub.m and Y'.sub.n are herein defined.

  公开了一种化学式为##STR1##的逆转录病毒蛋白酶抑制化合物，其中R.sub.1、R.sub.2、R.sub.5、R.sub.6、Y.sub.m和Y'.sub.n在此有定义。
• Intermediate for making retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05696270A1

  公开（公告）日：1997-12-09

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开一种化合物，其化学式为##STR1##，可抑制反转录病毒蛋白酶。
• Process for making retroviral protease inhibiting compounds
  申请人：Abbott Labortories

  公开号：US05892052A1

  公开（公告）日：1999-04-06

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开了一种化学式为##STR1##的逆转录病毒蛋白酶抑制剂。